Wall Street analysts expect Natus Medical Incorporated (NASDAQ:BABY) to post sales of $145.85 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Natus Medical’s earnings. The highest sales estimate is $146.20 million and the lowest is $145.50 million. Natus Medical posted sales of $107.70 million during the same quarter last year, which would suggest a positive year over year growth rate of 35.4%. The firm is expected to announce its next earnings report on Wednesday, February 7th.

On average, analysts expect that Natus Medical will report full-year sales of $145.85 million for the current fiscal year, with estimates ranging from $515.10 million to $515.70 million. For the next financial year, analysts expect that the company will post sales of $554.10 million per share, with estimates ranging from $552.40 million to $555.80 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Natus Medical.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million for the quarter, compared to analyst estimates of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. Natus Medical’s revenue was up 34.9% compared to the same quarter last year. During the same period last year, the company posted $0.39 earnings per share.

BABY has been the topic of several research reports. BidaskClub lowered shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, August 24th. Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $46.50.

In related news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $35.17, for a total transaction of $154,748.00. Following the transaction, the director now directly owns 50,850 shares of the company’s stock, valued at $1,788,394.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $42.91, for a total transaction of $542,468.22. Following the transaction, the vice president now directly owns 141,414 shares in the company, valued at $6,068,074.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,042 shares of company stock worth $902,266. 5.50% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. grew its holdings in Natus Medical by 2,085.6% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 2,607 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in Natus Medical by 90.9% in the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 1,364 shares during the last quarter. Sei Investments Co. grew its holdings in Natus Medical by 29.7% in the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after purchasing an additional 728 shares during the last quarter. SG Americas Securities LLC purchased a new position in Natus Medical in the third quarter worth $138,000. Finally, Victory Capital Management Inc. grew its holdings in Natus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock worth $140,000 after purchasing an additional 560 shares during the last quarter. 94.35% of the stock is currently owned by institutional investors and hedge funds.

Natus Medical (NASDAQ BABY) opened at $39.40 on Friday. The stock has a market cap of $1,227.47, a P/E ratio of 25.42 and a beta of 0.85. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical has a 1-year low of $31.65 and a 1-year high of $43.60.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Natus Medical Incorporated (BABY) Will Announce Quarterly Sales of $145.85 Million” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/03/brokerages-expect-natus-medical-incorporated-baby-will-announce-quarterly-sales-of-145-85-million.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.